Drug intelligence / Profile preview

Ewing Sarcoma Immunotherapy

Development stage: Preclinical
Lead developer: CancerVax
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Ewing Sarcoma Immunotherapy is a pre-clinical mRNA-based therapeutic being developed by CancerVax. It utilizes a proprietary "Smart mRNA" platform encapsulated in lipid nanoparticles (LNPs) to target Ewing sarcoma. The treatment's unique mechanism of action involves "disguising" cancer cells to express antigens associated with common childhood diseases, such as measles and chickenpox. By presenting these viral markers (referred to as Marker1 and Marker2) on the surface of tumor cells, the therapy aims to trigger a potent immune response by leveraging existing immune memory. The program is currently in the pre-clinical stage, with plans to initiate pre-IND animal studies in 2026.

Other names: CancerVax Ewing Sarcoma programEwing Sarcoma mRNA-LNP therapy

Targets

CD99 (CD99 molecule)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)

Beyond the preview

Go deeper on Ewing Sarcoma Immunotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ewing Sarcoma Immunotherapy.

Explore the full profile